|Bid||98.10 x 1000|
|Ask||98.93 x 900|
|Day's range||94.94 - 99.09|
|52-week range||91.66 - 114.36|
|Beta (5Y monthly)||0.99|
|PE ratio (TTM)||43.17|
|Earnings date||24 Apr 2023 - 28 Apr 2023|
|Forward dividend & yield||1.34 (1.28%)|
|Ex-dividend date||28 Feb 2023|
|1y target est||126.91|
Ashland (ASH) benefits from healthy demand in most consumer end markets, the Schulke & Mayr acquisition and its pricing and mix improvement actions to counter inflation.
Key Insights Ashland's estimated fair value is US$147 based on 2 Stage Free Cash Flow to Equity Ashland is estimated to...
Ashland (ASH) benefits from strength in its global pharma business, the Schulke & Mayr acquisition and its pricing and mix improvement actions to counter inflation.